Basic Rulide Information

• INN (International Nonproprietary Name): Roxithromycin.
• Brand Names Available In Australia: Rulide — tablets 150 mg (packs of 10) and 300 mg (packs of 5) supplied by Sanofi‑Aventis.
• ATC Code: J01FA06 (Antibacterials for systemic use; Macrolides; Roxithromycin).
• Forms & Dosages: Film‑coated tablets 150 mg and 300 mg (150 mg packs of 10; 300 mg packs of 5). Dispersible tablets or oral suspensions exist for generic roxithromycin in other countries.
• Manufacturers In Australia: Major supplier is Sanofi‑Aventis; generic roxithromycin is manufactured in other markets under the INN.
• Registration Status In Australia: Registered and approved by the TGA as Rulide 150 mg Aust R 39409 and Rulide 300 mg Aust R 42565.
• OTC / Rx Classification: Prescription Only Medicine (Rx) in all markets per available product information.

Latest Research Highlights

Worried about whether roxithromycin still works where you live?

Surveillance since 2022 across Australia and globally continues to show rising macrolide non‑susceptibility in key pathogens such as Streptococcus pneumoniae and Mycoplasma genitalium.

That trend affects empirical prescribing in community practice and increases the need to check local antibiograms before choosing a macrolide like roxithromycin.

Compared with azithromycin, roxithromycin has seen far fewer new large randomised controlled trials in 2022–2025, meaning direct head‑to‑head evidence is limited.

Smaller clinical studies and observational cohorts published in this period report roxithromycin’s efficacy in uncomplicated respiratory and skin infections with tolerability similar to other macrolides.

Safety monitoring via post‑marketing reports remains consistent with historical signals: mainly gastrointestinal adverse events and rare hepatic complications.

TGA registration and periodic safety update considerations continue to advise vigilance for liver issues and GI intolerance with roxithromycin.

Practice implication: stewardship‑first prescribing, tailor empirical choice to local resistance patterns and allergy profiles, and document rationale for macrolide use.

Clinical Effectiveness In Australia

Wondering how well Rulide performs for common infections in Australian primary care?

Rulide (roxithromycin) is effective for many community bacterial respiratory infections, skin and soft tissue infections and non‑gonococcal urethritis when the infecting organism is macrolide‑susceptible.

TGA registrations for Rulide 150 mg (Aust R 39409) and Rulide 300 mg (Aust R 42565) support these indications.

Australian primary‑care cohorts report typical symptom resolution during a 5–10 day course, with many uncomplicated infections responding to five days of therapy.

Effectiveness declines in areas with higher macrolide resistance, so state microbiology lab data and GP antibiograms should guide empirical therapy.

Practical advantage: the 300 mg once‑daily option can improve adherence compared with twice‑daily regimens, especially for patients juggling work or family duties.

When choosing between macrolides, note that head‑to‑head local outcome data versus azithromycin or clarithromycin are limited; clinical judgement and resistance data remain key.

PBS listing varies; if Rulide is not PBS‑subsidised for a given patient, expect private prescription costs and price variation across pharmacies.

Indications And Expanded Uses

Do you need Rulide for a throat infection, chest infection or something else?

TGA‑reflected indications for roxithromycin align with classical macrolide roles: pharyngitis and tonsillitis, bronchitis, mild to moderate community‑acquired pneumonia, skin and soft tissue infections (including impetigo), and non‑gonococcal urethritis.

Typical adult dosing from product information is 150–300 mg every 12 hours for pneumonia, 150 mg every 12 hours or 300 mg once daily for throat/respiratory/skin infections, and 300 mg once daily for non‑gonococcal urethritis.

Off‑label uses occasionally seen with specialist oversight include short‑term prophylaxis in selected ENT procedures or coverage for atypical pathogens where penicillin allergy limits options, but routine off‑label use is discouraged by stewardship principles.

Most treatment courses last five to ten days and should be tailored by infection site and clinical response.

Rulide is not active against viral infections such as colds or influenza, so testing or watchful waiting is appropriate when a viral cause is likely.

Composition And Brand Landscape

What exactly is in the tablet and who makes it?

The active ingredient is roxithromycin (INN); the Australian brand is Rulide, produced by Sanofi‑Aventis.

Rulide is sold as film‑coated tablets in 150 mg (packs of 10) and 300 mg (packs of 5).

ATC classification is J01FA06, placing roxithromycin in the macrolide antibacterials group.

Internationally the product appears as Rulid in some European markets and as generic roxithromycin formulations elsewhere, including tablets and sometimes dispersible or suspension forms.

Local generic availability in Australia depends on registration and pharmacy supply chains; substitution rules follow TGA and PBS guidance.

Major pharmacy chains and independent pharmacies may stock Rulide or source generics; stock can vary between urban and regional settings.

Contraindications And Special Precautions

Could Rulide be unsafe for you?

Absolute contraindications include known allergy to roxithromycin or other macrolide antibiotics such as azithromycin, clarithromycin or erythromycin.

Severe liver impairment is an absolute contraindication per product guidance and should prompt avoidance.

Relative contraindications requiring careful monitoring include pre‑existing liver disease, known QT prolongation or concurrent use of QT‑prolonging medicines, and concomitant use of ergot derivatives because of ergotism risk.

Special Australian population considerations include the elderly, who require monitoring of hepatic and renal function, and pregnancy and breastfeeding where a specialist consult is advised to balance risks and benefits.

Aboriginal and Torres Strait Islander peoples may need culturally safe explanations and accessible follow‑up because of higher comorbidity burdens and variable access to care.

There are no formal driving restrictions, but advise caution if dizziness or severe gastrointestinal symptoms occur.

Report significant adverse events to the TGA and check product information regularly for updates.

Dosage Guidelines

How should Rulide be dosed for different infections and patient groups?

Adult regimens from product information are: community‑acquired pneumonia 150–300 mg every 12 hours; throat/tonsil/respiratory/skin infections 150 mg every 12 hours or 300 mg once daily; non‑gonococcal urethritis 300 mg once daily.

Typical treatment durations are five to ten days depending on infection site and clinical response.

Children require weight‑based dosing, commonly 5–8 mg/kg/day, and paediatric formulations should be used where registered.

In the elderly, routine dose reduction is not normally required, but monitor hepatic and renal function and review interacting medicines.

Avoid roxithromycin in severe liver impairment and use caution in mild to moderate hepatic dysfunction with monitoring.

Kidney impairment generally requires no routine dose change because the drug is mainly metabolised by the liver, but monitor closely if renal failure is severe.

If a dose is missed, take it when remembered unless it is close to the next scheduled dose; do not double up.

Interactions Overview

Could roxithromycin clash with medicines you already take?

High‑risk interactions include ergot derivatives, which are contraindicated due to ergotism risk, and other QT‑prolonging medicines such as certain antiarrhythmics and some antipsychotics.

Though roxithromycin’s CYP interaction profile differs from clarithromycin, vigilance for drug interactions remains essential, particularly with drugs metabolised by hepatic enzymes.

Alcohol is not strictly prohibited, but heavy drinking can worsen gastrointestinal side effects and add to liver stress; counsel moderation.

Caffeine has no major direct pharmacological interaction, but it may increase gastrointestinal upset in susceptible patients.

Use real‑time clinical decision support at dispensing and review the patient’s My Health Record to flag interactions and document counselling, especially for rural patients with limited GP follow‑up.

Cultural Perceptions And Patient Habits

How do Australians approach antibiotics like Rulide?

Many Australians are pragmatic and price‑sensitive, and they trust pharmacists for clear advice on antibiotic need and duration.

Customers of major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart often expect price transparency and quick counselling at the counter.

Rural and remote communities rely more on telehealth and pharmacist consultations, and stockouts or supply variability can affect adherence.

Patient forums and social media show growing awareness of macrolide side effects and antibiotic stewardship, with requests for written instructions and return‑to‑work guidance.

Indigenous health settings require culturally appropriate explanations and reliable follow‑up to manage comorbidities and ensure safe treatment.

Telehealth e‑prescriptions make access easier but can increase private‑prescription use if PBS coverage is absent.

Availability And Pricing Patterns

Where can you get Rulide and what will it cost?

Rulide is registered in Australia with TGA numbers Rulide 150 mg Aust R 39409 and Rulide 300 mg Aust R 42565 and is typically stocked by major chains and independent pharmacies.

Pack sizes are 150 mg (packs of 10) and 300 mg (packs of 5).

If Rulide is not PBS‑subsidised for an individual patient, expect private prescription costs that vary between retailers and online pharmacies.

Chemist Warehouse often advertises lower retail prices, while Priceline and TerryWhite Chemmart may stock or source the product at different prices.

Rural patients may face higher freight or limited local stock, so plan ahead for continuity of therapy.

For cost‑sensitive patients, pharmacists can discuss generic roxithromycin if available or liaise with prescribers about clinically appropriate PBS‑listed alternatives.

In our online pharmacy, rulide is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Comparable Medicines And Preferences

Which macrolide might be better for a given patient?

Alternatives include azithromycin, clarithromycin and erythromycin, and choice depends on local resistance, dosing convenience, safety profile and cost.

Azithromycin offers shorter courses and good atypical coverage but faces rising resistance and some cardiac risk concerns.

Clarithromycin has a similar spectrum to roxithromycin but more CYP‑mediated interactions.

Erythromycin is older and more likely to cause gastrointestinal intolerance.

Roxithromycin pros include established use for common community infections and a 300 mg once‑daily option for adherence; cons include fewer recent large RCTs and resistance concerns in some areas.

Pharmacists should document rationale when recommending or substituting and consider the local antibiogram, patient allergies and PBS availability when advising prescribers or patients.

FAQ

Can I take Rulide for a sore throat?

If a GP suspects bacterial pharyngitis and prescribes a macrolide, roxithromycin is appropriate when macrolide therapy is indicated or when penicillin allergy prevents first‑line use.

Is Rulide on the PBS?

Check the PBS online for current listings and patient eligibility; if unsubsidised, pharmacies will quote a private price and may suggest alternatives.

Can I drink alcohol while taking roxithromycin?

Moderate alcohol is not strictly contraindicated, but avoid heavy drinking because of increased gastrointestinal upset and potential liver stress.

How soon will I feel better?

Many patients report symptom improvement within 48–72 hours; advise GP review if there is no improvement or symptoms worsen in that timeframe.

Guidelines For Proper Use

What should pharmacists cover when dispensing Rulide?

Confirm the indication and document allergies, including macrolide and penicillin allergies.

Review current medicines via My Health Record to check for QT‑prolonging drugs, ergot derivatives and other interactions.

Explain dosing clearly: 150 mg twice daily or 300 mg once daily depending on the condition, and usual durations of five to ten days.

Advise on missed doses, common adverse effects such as nausea and diarrhoea, and signs that require escalation such as rash, jaundice or severe abdominal pain.

For PBS matters, verify listing and concession eligibility before suggesting cost‑sensitive options, or propose clinically appropriate PBS alternatives where suitable.

Rural and remote counselling should include written instructions, telehealth follow‑up options and arranging postal delivery if local stock is limited.

Always report serious adverse events to the TGA and document counselling in the patient record.

Delivery Across Australia